EGFR blockade with ZD1839 (IRESSA) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinomaSOLOMON, Benjamin; HAGEKYRIAKOU, Jim; TRIVETT, Melanie K et al.International journal of radiation oncology, biology, physics. 2003, Vol 55, Num 3, pp 713-723, issn 0360-3016, 11 p.Article

Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cellsRODRIGUES, Sylvie; ATTOUB, Samir; GESPACH, Christian et al.Oncogene (Basingstoke). 2003, Vol 22, Num 29, pp 4488-4497, issn 0950-9232, 10 p.Article

Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumorsOCHS, Judith S.International journal of radiation oncology, biology, physics. 2004, Vol 58, Num 3, pp 941-949, issn 0360-3016, 9 p.Conference Paper

Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cellsCHEN, Yunhao; LOW, Teck-Yew; BIN LI et al.Proteomics (Weinheim. Print). 2007, Vol 7, Num 14, pp 2384-2397, issn 1615-9853, 14 p.Article

Protein kinase inhibitors : Structural insights into selectivity : Target specificity of effective anticancer therapeuticsTHAIMATTAM, Ram; BANERJEE, Rahul; MIGLANI, Rajni et al.Current pharmaceutical design. 2007, Vol 13, Num 27, pp 2751-2765, issn 1381-6128, 15 p.Article

EGFR regulates the side population in head and neck squamous cell carcinomaCHEN, Jocelyn S; PARDO, Francisco S; WANG-RODRIGUEZ, Jessica et al.The Laryngoscope. 2006, Vol 116, Num 3, pp 401-406, issn 0023-852X, 6 p.Article

A pharmacodynamic study of the Epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patientsDANESHMAND, Manijeh; PAROLIN, Doris A. E; LORIMER, Ian A. J et al.Clinical cancer research. 2003, Vol 9, Num 7, pp 2457-2464, issn 1078-0432, 8 p.Article

Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa)HUANG, Shyh-Min; JING LI; ARMSTRONG, Eric A et al.Cancer research (Baltimore). 2002, Vol 62, Num 15, pp 4300-4306, issn 0008-5472Article

Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulationDAVIS, Courtney; ABRAHAM, John.Sociology of health & illness (Print). 2011, Vol 33, Num 5, pp 731-747, issn 0141-9889, 17 p.Article

Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growthNORMANNO, N; CAMPIGLIO, M; DE LUCA, A et al.Annals of oncology. 2002, Vol 13, Num 1, pp 65-72, issn 0923-7534Article

Gefitinib (Iressa) pour le cancer pulmonaire non à petites cellules avancé = Gefitinib (Iressa) for advanced non-small cell lung cancerThe Medical letter on drugs and therapeutics (Edition française). 2002, Vol 24, Num 20, pp 89-90, issn 0253-8512, 2 p.Article

Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor iressa causes cooperative antitumor and antiangiogenic activityTORTORA, Giampaolo; CAPUTO, Rosa; DAMIANO, Vincenzo et al.Clinical cancer research. 2001, Vol 7, Num 12, pp 4156-4163, issn 1078-0432Article

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinaseSIROTNAK, Francis M; ZAKOWSKI, Maureen F; MILLER, Vincent A et al.Clinical cancer research. 2000, Vol 6, Num 12, pp 4885-4892, issn 1078-0432Article

Characterization of sequence-dependent synergy between ZD1839 ('Iressa') and oxaliplatinXU, Jian-Ming; AZZARITI, Amalia; SEVERINO, Montemuro et al.Biochemical pharmacology. 2003, Vol 66, Num 4, pp 551-563, issn 0006-2952, 13 p.Article

Synthesis of [¹¹C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinaseWANG, Ji-Quan; MINGZHANG GAO; MILLER, Kathy D et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 15, pp 4102-4106, issn 0960-894X, 5 p.Article

The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell linesXU, Jian-Ming; AZZARITI, Amalia; COLUCCI, Giuseppe et al.Cancer chemotherapy and pharmacology. 2003, Vol 52, Num 6, pp 442-448, issn 0344-5704, 7 p.Article

Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breastCHAN, Kai C; KNOX, W. Fiona; GEE, Julia M et al.Cancer research (Baltimore). 2002, Vol 62, Num 1, pp 122-128, issn 0008-5472Article

Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cellsFUJIMURA, Masaki; HIDAKA, Takao; SAITO, Shigeru et al.Clinical cancer research. 2002, Vol 8, Num 7, pp 2448-2454, issn 1078-0432Article

ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapyWAKELING, Alan E; GUY, Simon P; WOODBURN, Jim R et al.Cancer research (Baltimore). 2002, Vol 62, Num 20, pp 5749-5754, issn 0008-5472, 6 p.Article

Synthesis of [¹¹C]gefitinib for imaging epidermal growth factor receptor tyrosine kinase with positron emission tomographyHOLT, Daniel P; RAVERT, Hayden T; DANNALS, Robert F et al.Journal of labelled compounds & radiopharmaceuticals. 2006, Vol 49, Num 10, pp 883-888, issn 0362-4803, 6 p.Article

Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergyAOE, Keisuke; HIRAKI, Akio; MURAKAMI, Tomoyuki et al.Anticancer research. 2005, Vol 25, Num 1B, pp 415-418, issn 0250-7005, 4 p.Article

Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumorsGIACCONE, G; GONZALEZ-LARRIBA, J. L; FANDI, A et al.Annals of oncology. 2004, Vol 15, Num 5, pp 831-838, issn 0923-7534, 8 p.Article

Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase a type I causes potent antitumor, apoptotic, and antiangiogenic activityTORTORA, Giampaolo; CAPUTO, Rosa; DAMIANO, Vincenzo et al.Clinical cancer research. 2003, Vol 9, Num 2, pp 866-871, issn 1078-0432, 6 p.Article

Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cellsMATHENY, Keith E; BARBIERI, Christopher E; SNIEZEK, Joseph C et al.The Laryngoscope. 2003, Vol 113, Num 6, pp 936-939, issn 0023-852X, 4 p.Conference Paper

Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa)HEIMBERGER, Amy B; LEARN, Chris A; SAMPSON, John H et al.Clinical cancer research. 2002, Vol 8, Num 11, pp 3496-3502, issn 1078-0432, 7 p.Article